CSF3 and infection: In contrast to current economic evaluations comparing G-CSF vs. non-G-CSFs or long-acting G-CSF (e.g., pegfilgrastim) vs. short-acting G-CSF (e.g., filgrastim) that solely track FN events during chemotherapy cycles (Lyman et al., 2009; Whyte et al., 2011; Fust et al., 2014, 2015; Kulikov et al., 2016), the approach taken in this study broadens the scope to additional CIN complications including incidence of SN, infection and chemotherapy dose delay.